English
Deutsch
Español
Français
Polski
Português
Română
Русский
繁體中文

Stem Cell Treatment for Optic Nerve Hypoplasia / Septo Optic Dysplasia (ONH-SOD)

A combination of stem cells and extensive therapies giving the patient real chances of improvement

Restoring optic nerve function using stem cells

Optic nerve hypoplasia (ONH) occurs from the underdevelopment of the optic nerve, which carries neuronal transmission from the retina in the eye to the brain. Septo-optic dysplasia (SOD) – also known as de Morsier syndrome – is a subtype of ONH and results from underdevelopment of the optic nerve, pituitary gland dysfunction, and absence of the septum pellucidum, which is a midline area of the brain. SOD arises from defects during the embryological development of infants and studies show that ONH maybe be related to gene defects as well as embryo exposure to infections.

In addition to the lack of vision which a characteristic symptom of ONH, SOD also triggers other symptoms such as pituitary deficiency, autistic behaviors, epileptic seizures and more.

Few conventional treatment options are available for patients diagnosed with ONH-SOD, which mostly focus on helping the patients to cope with their disability. However, none of them are actually treating the loss of optic nerve function. Stem cells have the ability to regenerate nerve cells in the optic nerve, allowing ONH-SOD patients to gain some vision.

Why our stem cell treatment is effective for ONH/SOD

Since 2007, we have been developing comprehensive stem cell treatment protocols for Optic Nerve Hypoplasia (ONH) and Septo-Optic Dysplasia (SOD) to overcome the limitations of conventional therapies. In our protocols, stem cells are combined with specialized therapies for ONH-SOD that not only focus on helping the patient to cope with their symptoms, but also treat the root cause of the condition by promoting the healing of the optic nerve and other affected brain structures. We believe that our comprehensive treatment approach for ONH-SOD gives our patients the best chances for vision improvement, allowing for a better quality of life.

Possible improvements after Stem Cell Therapy for ONH/SOD

The purpose of our stem cell treatment for optic nerve hypoblasia/septo optic dysplasia is to restore neurological function in the brain area and in the optical nerve. Various kinds of improvement are possible after our comprehensive treatment. Past patients have experienced the following improvements*:

  • Sharpened visual acuity
  • Enhanced light perception
  • Enlarged visual field
  • Brighter night vision
  • Reduced nystagmus
  • Improved strabismus
  • Improved hormonal deficiencies
  • Decreased autistic symptoms

*It is important to remember that as for any medical treatment, improvements cannot be guaranteed. Please contact us for more information regarding the possible improvements for a particular case.

Our Treatment Program in Details

Beike is unlike any other stem cell treatment provider in the world, the reason? Since 2005, we have been developing and optimizing our stem cell treatment protocols with the concept that only a very comprehensive solution can allow our patients to truly benefit from stem cells. We believe that stimulation through various therapies is necessary to enhance stem cell regenerative response, therefore our protocols include daily therapies to support the stem cells. Finally, we provide a wide variety and large quantities of stem cells in order to adapt to each patient specific condition and deliver maximized regenerative potential.

Our stem cell treatment for optic nerve hypoplasia ONH-SOD consist in 6 to 8 simple and minimally invasive injections of umbilical cord derived stem cells. The stem cells are transplanted using two or three different methods: intravenous via a standard IV drip, through intrathecal injection. Patients older than 10 years old may also receive two retrobulbar injections to better target the optic nerves.* Together, these 3 injection methods allow for increased efficacy while ensuring safety and minimum inconvenience for the patient.

*Not all patients can receive a retrobulbar injection. The acting doctor will decide If it is possible.

  • 15 to 23 Days Stay
  • IV, Intrathecal and Retrobulbar Injections
  • UCBSC / UCMSC Cells
  • Daily Therapy Program
  • 120-400 Million Cells
  • Nutrition Program

Patient Experience Stories

Find out more about patients previously treated with Beike stem cell protocols. The families participating in these blog posts talk about their stories and present their own view of the treatment, including thoughts regarding the daily therapies, the stem cell injection themselves as well as improvement noticed during and after treatment.

Open letter from a patient’s mom

Sophie’s mom wrote us feedback in the form of a letter and with her consent, we decided to share it with you below… Sophie was born with Optic Nerve Hypoplasia, a rare genetic deficiency. She was diagnosed with chronic non-progressive encephalopathy, also known as cerebral palsy, when she was three …

Stem Cells for Optic Nerve Hypoplasia

Tell us about Gibson’s condition. How did you find out and what were your first thoughts? At my 18-week ultrasound, the anatomical measurements showed the baby’s head was a little larger than normal. My OBGYN sent me to a specialist. She ordered multiple tests and concluded that there was a …

ONH treatment for Lucas

“I only have good things to say about the team and the hospital.” In January 2020, Lucas came all the way from Brazil to Thailand for his first Stem Cell Therapy. Covid was just starting to catch our attention back in the day. Lucas was accompanied by his mom and …

Stem Cell Quality and Quantity Ensured

Packaging for Beike Biotechnology Stem Cell products

Different types of stem cells for different needs

Beike provides stem cells from two separate sources: umbilical cord blood and umbilical cord tissue. Umbilical cord related samples are donated by healthy mothers after normal births and are sent to Beike Biotech’s laboratories for processing.

After reviewing the patient’s full medical information, our doctors will recommend which source of stem cells should be used for treatment. Our treatment protocols may include one or multiple types of stem cells in combination depending on each patient’s specific condition.

Highest International Stem Cell Processing Standards

Beike Biotechnology is processing its own adult stem cells in its internationally accredited laboratories. The company has full control over the processing and quality control of all stem cell products, ensuring perfect safety and highest quality.

Stammzellenbehandlungen Doktor

Patient Videos

Below are video interviews recorded during treatment with Beike stem cells. The families showcased in these videos talk about their personal stories and their experience of the treatment including the improvement noticed.

The improvements mentioned in these videos are typical, however it does not guarantee that all patients may have the same improvements.

Why Choose Beike for a Stem Cell Treatment?

Experience: With more than a decade of practice, you are ensured to be advised and treated by competent professionals.

Safety: Accredited by the American Association of Blood Banks (AABB) and following highest international standards, our stem cell processing methods and laboratories ensure that you receive the best stem cell quality available.

Diversity: Multiple types of stem cells having different capabilities are available to adapt to each patient’s specific condition. We do not use the same type of stem cells for all patients.

Extensiveness: A complete supportive therapy program is provided daily to stimulate patient’s freshly transplanted stem cells. The best improvement can only be obtain by supporting your stem cells.

Support: A full follow-up program is provided after the treatment and you will be asked to take part in it at 1, 3, 6 and 12 months after treatment. Access to our team after the treatment is very important as you may receive further advice to maximize improvements.

Beike-Biotechnology head office building located in Shenzhen China

Founded in July 2005, Shenzhen Beike Biotechnology is a national high-tech enterprise specialized in clinical transformation and technical service of biological treatment technology of strategic emerging industries.

Get more information now


Frequently asked questions about ONH/SOD

References

  1. Júlio C. Voltarelli; Carlos E. B. Couri; Ana B. P. L. Stracieri; et al. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA. 2007;297(14):1568-1576.
  2. Giselle Chamberlain, James Fox, Brian Ashton et al. Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing. STEM CELLS 2007;25:2739 –2749.
  3. Myoung Woo Lee • In Keun Jang • Keon Hee Yoo et al. Stem and progenitor cells in human umbilical cord blood. Int J Hematol (2010) 92:45–51.
  4. Cun-Gang Fan & Qing-jun Zhang & Jing-ru Zhou. Therapeutic Potentials of Mesenchymal Stem Cells Derived from Human Umbilical Cord. 2010. Stem Cell Rev and Rep 9168-8.
  5. Annegret Dahlmann-Noon et al. Current approaches and future prospects for stem cell rescue and regeration of retina and optic nerve. can J Ophthalmol 2010;45:333-41.
  6. Naoko Koike Kiriyama et al. Human cord blood stem cells can differentiate into retinal nerve cells. Acta Neurobiol Exp 2007, 67;359-365.
  7. Rubens Camargo SiqueiraI; Júlio Cesar Voltarelli; André Marcio Vieira Messias; Rodrigo Jorge. Possible mechanisms of retinal function recovery with the use of cell therapy with bone marrow-derived stem cells.
  8. Tantai Zhao & Yunqin Li & Luosheng Tang et al. Protective effects of human umbilical cord blood stem cell intravitreal transplantation against optic nerve injury in rats. Graefes Arch Clin Exp Ophthalmol DOI 10.1007/s00417-011-1635-7.
  9. Yiming Huang & Volker Enzmann & Suzanne T. Ildstad. Stem Cell-Based Therapeutic Applications in Retinal Degenerative Diseases. Stem Cell Rev and RepDOI 10.1007/s12015-010-9192-8.
  10. Pinilla I, Martin Nieto J, Cuenca N. Stem Cell Potential Uses in Retinal Dystrophies. Arch Sic Esp Oftalmol 2007; 82: 127-128.
  11. Paul S. Baker and Gary C. Brown. Stem-cell therapy in retinal disease. Current Opinion in Ophthalmology 2009, 20:175–181.